Daxor Corporation

251 articles with Daxor Corporation

• Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference

  5/12/2022

  Daxor Corporation announces that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL.

• New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device

  5/2/2022

  Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced heart failure patients with left ventricular assist device (LVAD).

• New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure

  4/6/2022

  Daxor Corporation(Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart that was presented on April 2nd at the American College of Cardiology (ACC) 71st Scientific Sessions and Expo in Washington, DC.

• Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference

  3/23/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will present at Maxim Group 2022 Virtual Growth Conference to be held March 28-30, 2022, 9:00 AM - 5:30 PM ET.

• Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021

  3/1/2022

  Daxor Corporation, the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on February 28, 2022, disclosing its schedule of portfolio holdings as of December 31, 2021.

• Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure

  2/17/2022

  Daxor Corporation(Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF) patients published in the Journal of Cardiac Failure.

• Daxor Corporation Commences Trading on The NASDAQ Capital Market

  2/2/2022

  Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it commenced trading on the NASDAQ Capital Markets as of today, February 2, 2022.

• Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

  1/21/2022

  Daxor Corporation announced today that it has appointed Caleb DesRosiers, JD, MPA to its Board of Directors, effective January 18, 2022.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

  1/6/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

• Daxor Announces Key Milestones Achieved For Multicenter BVA-100® Study In Hospitalized Patients With COVID-19

  1/5/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 technology in hospitalized COVID-19 patients.

• DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

  1/4/2022

  Daxor Corporation today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways.

• Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

  11/16/2021

  Daxor Corporation today announces new data validating the benefits of the Company’s BVA-100 blood test in identifying heart failure patient-specific phenotypes and detecting true anemia.

• New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care

  11/9/2021

  Daxor Corporation(NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual NeuroCritical Care Society (NCS) 19th Annual Meeting.

• Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee

  10/1/2021

  The SBIR/STTR Matching Fund Grant Will Advance the Company’s Innovation and Commercialization Efforts, and Job Creation

• Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

  9/14/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021

• Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100® Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021

  9/8/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 – which brings together the world’s leading experts in heart failure from September 10-13, 2021.

• Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

  9/7/2021

  Daxor Corporation, the global leader in blood volume measurement technology, announces that President and Chief Executive Officer Michael Feldschuh will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.

• Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021

  8/30/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six months ended June 30, 2021.

• Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

  8/4/2021

  Daxor Corporation(NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data published in the journal Critical Care showing Daxor’s unique BVA-100 diagnostic blood test provides insights into the pathophysiology of volume derangements and capillary distress in critically ill COVID-19 patients enabling improved care.